NCT07470840Not yet recruitingPhase 2
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 1 Feb 2027
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- Fujian Cancer Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT07470840
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 27
- From 1 Feb 2027 to the primary completion date, 1 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- With contraindications to targeted or immunotherapeutic drugs.
- With severe uncontrolled recurrent infections or other serious uncontrolled concomitant diseases.
Other illness
- A history of other malignant diseases in the recent 5 years, except for cured skin cancer and carcinoma in situ of the cervix.
- With active autoimmune diseases, organ transplantation, or other diseases requiring immunosuppressive therapy or long-term hormone therapy.
- A history of uncontrolled epilepsy, central nervous system diseases or mental disorders, whose clinical severity is judged by the investigator to potentially hinder the signing of the informed consent form or affect the patient's compliance with oral medication.
- Allergic to any component of the study drugs.
Lab values
- The subject's baseline blood routine and biochemical indicators do not meet the following criteria: hemoglobin ≥80g/L; absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet ≥100×10⁹/L; ALT and AST ≤2.5 times the upper limit of normal; serum total bilirubin \<1.5 times the upper limit of normal; serum creatinine \<2 times the upper limit of normal.
Other
- Extensive diffuse metastasis with an expected survival of less than 3 months.
Who the study is looking for
- Aged 18 to 80 years, regardless of sex.
- Histologically or cytologically confirmed locally advanced/metastatic renal cell carcinoma (RCC) inoperable/refused for surgery, or post-operative locally recurrent/metastatic RCC; pathological types include clear cell carcinoma and papillary renal cell carcinoma.
- ECOG performance status 0 or 1.
- At least 50% of all evaluable metastatic lesions are eligible for stereotactic body radiation therapy (SBRT).
- No contraindications to radiotherapy, targeted therapy or immunotherapy.
- At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Capable and willing to comply with the study protocol including scheduled visits, treatment plan, laboratory tests and other study-related procedures during the study period.
- Signed written informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.